Table 3 Inflammatory mediator profiles
Inflammatory mediators | CARDS cases (n = 16) | IC controls (n = 12) | Healthy controls (n = 12) | p-valuea |
|---|---|---|---|---|
IFN-α1 | 7 (6, 8) | 9 (7, 11) | 7 (6, 7) | 0.065 |
IFN-α16 | 12 (10, 30) | 30 (26, 30) | 11 (11, 30) | 0.2 |
IFN-α17 | 8.7 (7.9, 10.6) | 9.4 (8.4, 10.6) | 8.2 (7.4, 9.0) | 0.13 |
IFN-α2 | 9 (8, 10) | 9 (9,11) | 8 (8, 9) | 0.2 |
IFN-α6 | 7.7 (7.0, 9.0) | 8.2 (7.4, 9.2) | 7.0 (6.6, 7.5) | 0.2 |
IFN-α7 | 7.21 (6.86, 9.03) | 9.35 (8.14,10.00) | 7.19 (6.89, 7.82) | 0.024 |
IFN-α8 | 9 (8, 10) | 9 (8, 10) | 8 (7, 8) | 0.038 |
IFN-β1 | 8 (8, 10) | 8 (8, 10) | 8 (7, 9) | 0.3 |
IFN-γ | 30 (30, 30) | 30 (-11, 30) | 30 (30, 30) | 0.041 |
IL10 | 30 (30, 30) | 30 (30, 30) | 30 (26, 30) | 0.2 |
IL-12α | 30 (30,30) | 30 (30, 30) | 30 (30, 30) | 0.7 |
IL-12β | 30 (21, 30) | 30 (30, 30) | 30 (30, 30) | 0.4 |
IL-13 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.094 |
IL-15 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | > 0.9 |
IL-16 | 30 (30, 30) | 22 (12, 30) | 30 (30, 30) | 0.3 |
IL-17α | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.3 |
IL-18 | 30 (30, 30) | 30 (26, 30) | 30 (30, 30) | 0.2 |
IL-1 A | 30 (25, 30) | 30 (12, 30) | 30 (30, 30) | 0.068 |
IL-1β | 10 (8, 30) | 12 (11, 30) | 30 (30, 30) | 0.005 |
IL-2 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.5 |
IL-3 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.5 |
IL-4 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.2 |
IL-5 | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.7 |
IL-6 | 30 (25, 30) | 30 (26, 30) | 30 (10, 30) | 0.6 |
IL-8 | 21 (8, 30) | 12 (10, 30) | 30 (13, 30) | 0.3 |
IL-9 | 12 (10, 30) | 30 (30, 30) | 30 (14, 30) | 0.014 |
LTA | 30 (30, 30) | 30 (30, 30) | 30 (30, 30) | 0.3 |
TNF | 30 (16, 30) | 30 (11, 30) | 30 (30, 30) | 0.2 |